Analysts Are Bullish on Top Services Stocks: NV5 Holdings (NVEE), VolitionRX (VNRX)

By Jason Carr

There’s a lot to be optimistic about in the Services sector as 2 analysts just weighed in on NV5 Holdings (NVEEResearch Report) and VolitionRX (VNRXResearch Report) with bullish sentiments.

NV5 Holdings (NVEE)

In a report released today, Tate Sullivan from Maxim Group maintained a Buy rating on NV5 Holdings, with a price target of $85. The company’s shares closed on Friday at $62.84.

Sullivan commented:

“Based on NVEE acquisitions and a potential increase in administrative costs as a percent of revenue after acquisitions, we decrease our 2019 GAAP EPS forecast to $2.63 (from $2.78) and our 2020 GAAP EPS to $3.47 (from $3.56).”

According to TipRanks.com, Sullivan is a 3-star analyst with an average return of 5.1% and a 66.7% success rate. Sullivan covers the Basic Materials sector, focusing on stocks such as Natural Gas Services Group, Emcor Group, and Tetra Tech.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NV5 Holdings with a $91.50 average price target.

See today’s analyst top recommended stocks >>

VolitionRX (VNRX)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on VolitionRX, with a price target of $6. The company’s shares closed on Friday at $3.46, close to its 52-week high of $3.52.

McCarthy noted:

“VolitionRx held a capital markets day on 4/9 at the NYSE to highlight its R&D programs including Nu.Q for colorectal cancer (CRC) and lung cancer, as well as programs such as Nu.Q Vet (which could reach the market as early as 2020), and Nu.Q Capture.”

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -8.4% and a 30.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

VolitionRX has an analyst consensus of Moderate Buy, with a price target consensus of $5.50, a 59.0% upside from current levels. In a report issued on April 10, Oppenheimer also assigned a Buy rating to the stock with a $5 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.